Capivasertib (AZD5363)

Catalog No.S8019

Capivasertib (AZD5363) Chemical Structure

Molecular Weight(MW): 428.92

AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.

Size Price Stock Quantity  
In DMSO USD 235 In stock
USD 147 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 16 Publications

6 Customer Reviews

  • HEK293T cells stably expressing mTOR mutants (H1968Y, P2213S, and S2215Y) were constructed by TALEN. After nutrient starvation, wild-type (WT, for HEK293T cells not expressing mutants but wild-type mTOR after TALEN edition and selection) or mutated HEK293T cells (heterozygous, A) were treated with indicated inhibitors or vehicle. The activation of indicated molecules was examined by Western blotting.

    Clin Cancer Res, 2016, 22(4):1018-27. Capivasertib (AZD5363) purchased from Selleck.

    G-H. Analysis of cells treated with AZD5363 (500 nM) for 24 hrs. G.Western analysis of whole cell lysates. H. Cells labeled with Annexin V-FITC for 6h were imaged. Individual points are average for replicates assessed in duplicate. Midlines are the average ± S.D. Student’s T-test.

    Cancer Res, 2016, 76(16):4752-64.. Capivasertib (AZD5363) purchased from Selleck.

  • Inhibition of PI3K and Akt by LY294002 and AZD5363 was confirmed by analyzing expression and activation status of the ribosomal protein S6 by Western blot analysis of PC-3 clone #14 cells treated with 0.5 or 5 uM AZD5363 (AZD) and 10 uM LY294002 (LY). Tubulin was used as a loading control.

    Cell Commun Signal 2014 12(1), 61. Capivasertib (AZD5363) purchased from Selleck.

    e HSP70 release induced by morphine was abrogated by AKT inhibitor. AZD5363 (AKT inhibitor, 2 μM) was given 15 min before morphine (200 μM, 12 h). Supernatants were collected and analyzed 12 h after morphine exposure (n = 3)

    J Neuroinflammation, 2017, 14(1):228. Capivasertib (AZD5363) purchased from Selleck.

  • (A) 239 cells stably expressing Flag-IL-17RA (293-IL-17RA cell line) were treated with 2 μM AZD5363 (a pan-Akt inhibitor) and/or 50 ng/ml insulin for the indicated time periods; Western blot analysis was performed for the indicated proteins; exogenous, IL-17RA transfected into 293 cells; endogenous, endogenous IL-17RA expressed in 293 cells.

    Oncotarget, 2016, 7(12):13651-66. Capivasertib (AZD5363) purchased from Selleck.

    LNCaP, LNCaP95, VCaP and 22Rv1 cells were transfected with control or pooled siRNA for AKT 1–3 isoforms for 36 hours. Cells were then further treated with 5 uM AZD5363 (B) for another 18 hours. Protein lysates were immunoblotted with AR (N-20), AR-V7, Pan-AKT, p-AKT(ser473) and β-Actin antibodies. Results were repeated in more than three independent experiments.

    PLoS One 2014 9(10), e108780. Capivasertib (AZD5363) purchased from Selleck.

Purity & Quality Control

Choose Selective Akt Inhibitors

Biological Activity

Description AZD5363 potently inhibits all isoforms of Akt(Akt1/Akt2/Akt3) with IC50 of 3 nM/8 nM/8 nM in cell-free assays, similar to P70S6K/PKA and lower activity towards ROCK1/2. Phase 2.
Features Moderate preclinical tolerability, and PD characteristics of an AKT inhibitor. Distinct profile from other AKT inhibitors in clinical development.
Targets
Akt1 [1]
(Cell-free assay)
Akt2 [1]
(Cell-free assay)
Akt3 [1]
(Cell-free assay)
ROCK2 [1]
(Cell-free assay)
3 nM 8 nM 8 nM 56 nM
In vitro

AZD5363 is a potent Akt inhibitor with IC50 of 3 nM, 8 nM and 8 nM for Akt1, Akt2 and Akt3, respectively. [1] AZD5363 inhibits phosphorylation of AKT substrates in cells with a potency of approximately 0.3 to 0.8 μM. AZD5363 inhibits the proliferation of 41 of 182 solid and hematologic tumor cell lines with a potency of < 3 μM. [2] Activating mutations in PIK3CA, loss or inactivation of tumor suppressor PTEN, or HER2 amplification all are significantly predictive of responsiveness to AZD5363. Additionally, correlation is also seen between the RAS mutation status of cell lines and resistance to AZD5363. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MljPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFGxWIczODBibl2= NUjsSohuPiCm NX62WnlocW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 NEfVZ4IzPjN3MUOyNy=>
ZR75 NFfTSppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDCSpJPOTByIH7N MXK2JIQ> M37LWIlv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= MYeyOlM2OTN{Mx?=
T74D NHnFbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy4fZQyOTByIH7N NGnROno3KGR? NXKxfm92cW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 M2m3PFI3OzVzM{Kz
1%MCF7 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYX2NJdoPDByIH7N MYO2JIQ> NX;mVI97cW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 M{j5Z|I3OzVzM{Kz
MCF7 LTED M3P6XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXuzVVN[OjByIH7N M2fxTFYh\A>? MnzibY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 MljyNlY{PTF|MkO=
ZR75 LTED MkOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;JU2N4OTByIH7N MWG2JIQ> NUT3R25ocW6lcnXhd4VlKGS{dXegd4Vve2m2aY\peJkhd2ZiND3PTHQh[W6mIH\1cJZme3S{YX70 MWmyOlM2OTN{Mx?=
T74D LTED NXXFSpF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVKxNFAhdk1? NWrlVlhCPiCm MmDRbY5kemWjc3XkJIRzfWdic3Xud4l1cX[rdImgc4YhPC2RSGSgZY5lKG[3bI\ld5Rz[W62 NGS2cVkzPjN3MUOyNy=>
TamR NYOySWE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjEOoo1ODBibl2= NVnGSmJTPiCm M3HJPIlv[3KnYYPl[EBlenWpIIPlcpNqfGm4aYT5JI9nKDRvT1jUJIFv\CCodXz2[ZN1emGwdB?= Mn3kNlY{PTF|MkO=
HCC1954 Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknpNE0yNjN3IN88US=> MlPvOUBl MoHs[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF? M1\NSVI3ODl3NEe1
BT474c MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17TZVAuOS5|NTFOwG0> NVTXcYVNPSCm NHP5OWlmdmijbnPld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[gRXpFQDl|MR?= NHvW[FIzPjB7NUS3OS=>
KPL4 M4ntSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV2wMVEvOzVizszN NYrkNJhOPSCm NIDZdopmdmijbnPld{B1cGViZ4Lve5RpKGmwaHnibZRqd25ib3[gRXpFQDl|MR?= NVTTVY91OjZyOUW0O|U>
SKBR3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn:wNE0yNjN3IN88US=> M33QN|Uh\A>? MlGx[Y5p[W6lZYOgeIhmKGe{b4f0bEBqdmirYnn0bY9vKG:oIFHaSFg6OzF? MlvRNlYxQTV2N{W=
MR49C M4\VOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWHsWWtjOC13IN88US=> M3\l[lQ5KGh? NWLYVVhmcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJ? MWmyOVE2OTBzMh?=
MR49F NUfNfJZNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV:wMVUh|ryP NETSZVI1QCCq MWfpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uh\GWyZX7k[Y51KG2jbn7ldi=> MnjJNlUyPTFyMUK=
NCI-H522 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUTN[FIyUUN3ME2xNU4{KCkEsUKuO{kh|ryP NXz0WpdEOjR7NUe2PFI>
PC-9 NGfNPWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF24Z2NKSzVyPUmuN{ApyrFzLkKpJO69VQ>? M4XWOFI1QTV5Nkiy
NCI-H522 NFnUXpZHfW6ldHnvckBCe3OjeR?= Mk\CNU82NzFyIN88US=> NXHOOIdDPC9{NDDo MV;pcoNz\WG|ZYOgRWtVKHCqb4PwbI9zgWyjdHnvci=> NGHEeYMzPDl3N{[4Ni=>
PC-9 NULoV3RWTnWwY4Tpc44hSXO|YYm= MmWxNU82NzFyIN88US=> Mn[zOE8zPCCq M2XXbIlv[3KnYYPld{BCU1RicHjvd5Bpd3K7bHH0bY9v NFrPdZMzPDl3N{[4Ni=>
HGC27 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTBwNES1JO69VQ>? NYHLd|FrOjRyOEizPFI>
IM95m MkPwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTTTnpKSzVyPUCuOVEh|ryP MWCyOFA5QDN6Mh?=
AGS M3W5O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTBwNUWyJO69VQ>? MXuyOFA5QDN6Mh?=
NCI-N87 NHXJOmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofpTWM2OD1zLkCzO{DPxE1? MYmyOFA5QDN6Mh?=
23132/87 M1HiUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NITmO5ZKSzVyPUGuOlcyKM7:TR?= M3zE[|I1ODh6M{iy
MKN1 M4TURWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXCbYVKSzVyPUKuOFIyKM7:TR?= M3rUN|I1ODh6M{iy
SNU-620 MlvoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVL3[3dQUUN3ME2zMlM5PCEQvF2= M3TpPVI1ODh6M{iy
SNU-638 NEHTdW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTRwNUKzJO69VQ>? NULI[JhiOjRyOEizPFI>
SNU-1 NILvb5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13BS2lEPTB;NT6yOVgh|ryP MkfSNlQxQDh|OEK=
SNU-601 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkLBTWM2OD13LkmzPEDPxE1? NGTVdm8zPDB6OEO4Ni=>
SNU-668 M{LscWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml72TWM2OD14LkCwN{DPxE1? NYPLb|R1OjRyOEizPFI>
HS746T NUHIbppYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGO4RllKSzVyPU[uNFg1KM7:TR?= MYOyOFA5QDN6Mh?=
KATO III NE\rS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfTNoVLUUN3ME23MlI3PyEQvF2= NUnUZllrOjRyOEizPFI>
SNU-484 M2j0dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvCOIVKSzVyPUeuN|kzKM7:TR?= NGDmSY0zPDB6OEO4Ni=>
SNU-16 NHXGelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlz3TWM2OD1zMT6wPVch|ryP NIOxcnEzPDB6OEO4Ni=>
OCUM-1 NHXPdJdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmGyTWM2OD1zND61NVUh|ryP NYmyWXFGOjRyOEizPFI>
NUGC-3 M3vjS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTaS5U{UUN3ME2yNU45PzNizszN MoHXNlQxQDh|OEK=
AZ521 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DIOGlEPTB;MkWuOFQ5KM7:TR?= NX7ZToh3OjRyOEizPFI>
SNU-216 NYOyfWI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnHUWZvUUN3ME2zNEDPxE1? NH74UIYzPDB6OEO4Ni=>
NUGC-4 NGr0[4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DrWmlEPTB;M{Cg{txO MVeyOFA5QDN6Mh?=
SNU-5 NXrqS41[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTNyIN88US=> NWjSU3J2OjRyOEizPFI>
GTL-16 NILsOY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTNyIN88US=> MYCyOFA5QDN6Mh?=
MKN74 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYGwWllDUUN3ME2zNEDPxE1? MlzyNlQxQDh|OEK=
PAMC82 NVmyeoFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWG0Tlc2UUN3ME2zNEDPxE1? MYKyOFA5QDN6Mh?=
LNCaP Mk\LSpVv[3Srb36gRZN{[Xl? MnW0OUDPxE1? NHmzNokxNTJ2IHi= M1jZSYlv\HWlZYOgRWtVWzR5MzDhcoQhSUuWVEOwPEBxcG:|cHjvdplt[XSrb36gbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK= Ml:xNlM6PjZ4MkG=
C4-2  M2W0R2Z2dmO2aX;uJGF{e2G7 NHLqcYI2KM7:TR?= MmPFNE0zPCCq M4W1UYlv\HWlZYOgRWtVWzR5MzDhcoQhSUuWVEOwPEBxcG:|cHjvdplt[XSrb36gbY4h[SC2aX3lJIRmeGWwZHXueEBu[W6wZYK= M3HteFI{QTZ4NkKx
LNCaP NEDk[VNHfW6ldHnvckBCe3OjeR?= MYe1JO69VQ>? M4O5RVAuOjRiaB?= M4DaNYlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kB1cGViZHnzeIFtKEGNVD3wZZRpf2G7IHLpc41iemuncoOgbY5kdHWmaX7nJHBTSVN2MDyg[WlHPEVuIETFMWJROSxibWTPVkwh[W6mIGC3NEBUPiCtaX7hd4UhcW5iYTD0bY1mNWSncHXu[IVvfCCvYX7u[ZI> MnHENlM6PjZ4MkG=
C4-2  MnzTSpVv[3Srb36gRZN{[Xl? NXLGSFFmPSEQvF2= M1\i[VAuOjRiaB?= MlzqbY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJJRp\SCmaYP0ZYwhSUuWLYDheIh4[XliYnnvcYFzc2W{czDpcoNtfWSrbnegVHJCWzRyLDDlTWY1TSxiNFWtRnAyNCCvVF;SMEBidmRiUEewJHM3KGurbnHz[UBqdiCjIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NHTMN4wzOzl4Nk[yNS=>
LNCaP NV;Db|hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfPVpQyNTFyMECwJI5O MkfJNE0{KGR? NYi2WXFzcW6qaXLpeJMh[2WubDD2bYFjcWyrdImg[I9{\SCmZYDlcoRmdnSueR?= Mn\DNlM6PjZ4MkG=
C4-2  NGPoWpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYTjT3pXOS1zMECwNEBvVQ>? MUKwMVMh\A>? Mni3bY5pcWKrdIOgZ4VtdCC4aXHibYxqfHliZH;z[UBl\XCnbnTlcpRtgQ>? Ml\TNlM6PjZ4MkG=
LNCaP MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXm[VEyODBvNUCwNEBvVQ>? M1;2WVczKGh? NVP5WI1RcW6lcnXhd4V{KHSqZTDmdoFkfGmxbjDv[kBk\WyuczD1coRmemexaX7nJINmdGxiZHXheIg> NHHaZVczOzl4Nk[yNS=>
C4-2  M3LhUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVexNFAuPTByMDDuUS=> NYrmOXF{PzJiaB?= MWjpcoNz\WG|ZYOgeIhmKG[{YXP0bY9vKG:oIHPlcIx{KHWwZHXy[49qdmdiY3XscEBl\WG2aB?= NW\EUI1oOjN7Nk[2NlE>
PC-3 MofqSpVv[3Srb36gRZN{[Xl? MmDONE42NzFxMUCg{txO MUW0PEBp M{npd4Rwf26{ZXf1cIF1\XNidHjlJJBpd3OyaH;yfYxifGmxbjDv[kBld3ewc4Ty[YFuKHCjdHj3ZZkheHKxdHXpcpMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI> M2TkUlI{OjV6N{Sw
DU145  M4fFXWZ2dmO2aX;uJGF{e2G7 MVWwMlUwOS9zMDFOwG0> M13wRlQ5KGh? NEXte4pld3ewcnXneYxifGW|IITo[UBxcG:|cHjvdplt[XSrb36gc4Yh\G:5boP0doVidSCyYYToe4F6KHC{b4TlbY5{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M17odVI{OjV6N{Sw
LNCaP M{XBdGNmdGxiVnnhZoltcXS7IFHzd4F6 M4L3blAuOTByMDDuUS=> MkLENE01KGR? MmexdoVlfWOnZDDMUmNiWCClZXzsJJZq[WKrbHn0fUBqdiCjIHTvd4UuKGGwZDD0bY1mNWSncHXu[IVvfCCvYX7u[ZLDqA>? NVXjOVJMOjN{NUi3OFA>
PC-3  NWrKRZJjTnWwY4Tpc44hSXO|YYm= MmrvNVAh|ryP MlzuNVIhcA>? MVzpcoR2[2W|IHH1eI9xcGGpeR?= M37xO|I{OjV6N{Sw

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of AZD5363 (100, 300 mg/kg) to nude mice causes dose- and time-dependent reduction of PRAS40, GSK3β, and S6 phosphorylation in BT474c xenografts, reversible increases in blood glucose concentrations, and dose-dependent decreases in 2[18F]fluoro-2-deoxy-d-glucose (18F-FDG) uptake in U87-MG xenografts. Chronic oral dosing of AZD5363 (130, 200, and 300 mg/kg) causes dose-dependent growth inhibition of xenografts derived from various tumor types, including HER2+ breast cancer models that are resistant to trastuzumab. AZD5363 also significantly enhances the antitumor activity of docetaxel, lapatinib, and trastuzumab in breast cancer xenografts. [2]

Protocol

Kinase Assay:[1]
+ Expand

Caliper Off-Chip Incubation Mobility Shift assay:

The ability of AZD5363 and other compounds to inhibit the activity of AKT1, AKT2, and AKT3 is evaluated by the Caliper Off-Chip Incubation Mobility Shift assay. Active recombinant AKT1, AKT2, or AKT3 are incubated with a 5-FAM-labeled custom-synthesized peptide substrate together with increasing concentrations of inhibitor. Final reactions contained 1 to 3 nM AKT1, AKT2, or AKT3 enzymes; 1.5 mM peptide substrate; ATP at K m for each AKT isoform; 10 mM MgCl2, 4 mM DTT, 100 mM HEPES, and 0.015% Brij-35. The reactions are incubated at room temperature for 1 hour and stopped by the addition of buffer containing 100 mM HEPES, 0.015% Brij-35 solution, 0.1% coating reagent, 40 mM EDTA, and 5% DMSO. Plates are then analyzed using a Caliper LC3000, allowing for separation of peptide substrate and phosphorylated product by electrophoresis with subsequent detection and quantification of laser induced fluorescence.
Cell Research: [2]
+ Expand
  • Cell lines: 182 solid and hematologic tumor cell lines
  • Concentrations: ~30 μM
  • Incubation Time: 72 hours
  • Method: Cell proliferation assay is determined by 2 methods, MTS and Sytox Green. Briefly, cells are seeded in 96-well plates and incubated overnight at 37 ℃, 5% CO2. Cells are then exposed to concentrations of AZD5363 ranging from 30 to 0.003μM for 72 hours. For the MTS endpoint, cell proliferation is measured by the CellTiter AQueous Non-Radioactive Cell Proliferation Assay reagent in accordance with the manufacturer's protocol. For the Sytox Green endpoint, Sytox Green nucleic acid dye diluted in TBS-EDTA buffer is added to cells (final concentration of 0.13 μM) and the number of dead cells detected using an Acumen Explorer. Cells are then permeabilized by the addition of saponin (0.03% final concentration, diluted in TBS-EDTA buffer), incubated overnight and a total cell count measured. Predose measurements are made for both MTS and Sytox Green endpoints, and concentration needed to reduce the growth of treated cells to half that of untreated cells values are determined using absorbance readings (MTS) or live cell counts.
    (Only for Reference)
Animal Research:[2]
+ Expand
  • Animal Models: Female nude mice and male SCID mice with BT474c, U87MG, KPL-4, HCC-1187 xenografts.
  • Formulation: In 10% DMSO 25% w/v Kleptose HPB
  • Dosages: 130 mg/Kg - 300 mg/Kg
  • Administration: p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 86 mg/mL (200.5 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
1% CMC Na
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.92
Formula

C21H25ClN6O2

CAS No. 1143532-39-1
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03310541 Recruiting Breast Cancer|Prostate Cancer|Advanced Solid Tumors Memorial Sloan Kettering Cancer Center October 11 2017 Phase 1
NCT03182634 Recruiting Advanced Breast Cancer Institute of Cancer Research United Kingdom|Royal Marsden NHS Foundation Trust December 15 2016 Phase 2
NCT02576444 Recruiting Cancer Joseph Paul Eder|Dana-Farber Cancer Institute|Vanderbilt-Ingram Cancer Center|The Cleveland Clinic|Yale University November 2015 Phase 2
NCT02664935 Recruiting Non-Small Cell Lung Cancer|Carcinoma Squamous Cell|Adenocarcinoma University of Birmingham|Cancer Research UK|AstraZeneca|Pfizer|Experimental Cancer Medicine Centre Network|Mirati Therapeutics Inc. May 2015 Phase 2
NCT02449655 Recruiting Advanced Gastric Adenocarcinoma Samsung Medical Center February 12 2015 Phase 2
NCT02451956 Recruiting Advanced Gastric Cancer Samsung Medical Center January 7 2015 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Akt Signaling Pathway Map

Akt Inhibitors with Unique Features

Related Akt Products4

Tags: buy Capivasertib (AZD5363) | Capivasertib (AZD5363) supplier | purchase Capivasertib (AZD5363) | Capivasertib (AZD5363) cost | Capivasertib (AZD5363) manufacturer | order Capivasertib (AZD5363) | Capivasertib (AZD5363) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID